Chronic Nos Inhibition Actuates Endothelial-mesenchymal Transformation.
From: New York Medical College, Basic Sciences Bldg., Rm. C23, Valhalla, NY 10595, USA.
American journal of physiology. Heart and circulatory physiology
- Publish Date: Jan 2007
- ISSN: 0363-6135
- Volume: 292
- Issue: 1
- Pages: H285-94
- Medium: Print
- Language: English
- Citation (JAMA): O'Riordan Edmond, Mendelev Natalia, Patschan Susann, et al. Chronic Nos Inhibition Actuates Endothelial-mesenchymal Transformation.. Am. J. Physiol. Heart Circ. Physiol. Jan 2007;292:H285-94
Abstract
Chronic kidney diseases are accompanied by the accumulation of substances like asymmetric dimethylarginine, phenylacetic acid, homocysteine, and advanced glycation end products, known to either inhibit endothelial nitric oxide synthase (eNOS) or uncouple it, consequently limiting the amount of available nitric oxide (NO). Reduced bioavailability of NO induces endothelial dysfunction. An early loss of peritubular capillaries in tubulointerstitial fibrotic areas and injury to endothelial cells have been linked to progressive renal disease. Screening endothelial genes in cells treated with NOS inhibitors showed upregulation of collagen XVIII, a precursor of a potent antiangiogenic substance, endostatin. This finding was confirmed at the level of mRNA and protein expression. Tie-2 promoter-driven green fluorescent protein mice treated with nonhypertensinogenic doses of a NOS inhibitor exhibited upregulation of collagen XVIII/endostatin and rarefaction of capillary profiles. This was accompanied by the increased expression of transforming growth factor-beta and connective tissue growth factor in the kidney. Occasional endothelial cells expressed both the marker of endothelial lineage (green fluorescent protein) and mesenchymal marker (alpha-smooth muscle actin or calponin). In vitro studies of endothelial cells treated with asymmetric dimethylarginine showed decreased expression of eNOS and Flk-1 and enhanced expression of calponin and fibronectin, additional markers of smooth muscle and mesenchymal cells. These cells overexpressed transforming growth factor-beta and connective tissue growth factor, as well as endostatin. In conclusion, data presented here 1) ascribe to NO deficiency in endothelial cells the function of a profibrotic stimulus associated with the expression of an antiangiogenic fragment of collagen XVIII (endostatin) and 2) provide evidence of endothelial-mesenchymal transdifferentiation in the course of inhibition of NOS by a pathophysiologically important antagonist, asymmetric dimethylarginine. Both mechanisms may account for microvascular rarefaction.
Mesh Headings (Keywords): Animals, Cell Differentiation, Cells, Cultured, Endothelial Cells, Endothelial Growth Factors, Enzyme Inhibitors, Humans, Mesenchymal Stem Cells, Mice, Mice, Knockout, Nitric Oxide, Nitric Oxide Synthase, Transforming Growth Factors
Check for Full Text / PubMed Unique Identifier (PMID): 16963618
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.